Heteropolymers: A novel technology against blood-borne infections

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 2, 2005, Pages 144-150

  Mohamed, Nehal ^a   Jones, Steven M ^a   Casey, Leslie S ^a   Pincus, Steven E ^a   Spitalny, George L ^b  

^a Elusys Therapeutics Inc   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Blood borne; Complement receptor type 1; Heteropolymers; Immune adherence; Immune complex; Red blood cell

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY CONJUGATE; ANTIGEN; BLOOD GROUP ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DOUBLE STRANDED RNA; ETI 104; FC RECEPTOR; HETEROPOLYMER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYMER; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BACTERIOPHAGE PHI X 174; CLINICAL TRIAL; CROSS LINKING; DENGUE VIRUS; DRUG BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTE; HUMAN; IMMOBILIZED CELL; IMMUNE ADHERENCE; IN VITRO STUDY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; REVIEW; SEPSIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; VIREMIA; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASES; HUMANS; MICE; RECEPTORS, COMPLEMENT;

ANIMALIA; PRIMATES;

EID: 17144404875     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Nelson RA Jr: The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science (1953) 118 3077):733-737.
2. Cornacoff JB, Hebert LA, Smead WL, VanAman ME, Birmingham DJ, Waxman FJ: Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 71(2):236-247.
3. Fearon DT: Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 152 1):20-30.
4. Lindorfer MA, Hahn CS, Foley PL, Taylor RP. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: Mechanisms and applications. Immunol Rev (2001) 183:10-24.
5. Nardin A, Lindorfer MA, Taylor RP: How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol (1999) 36(13-14):827-835.
6. Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W, Taylor RP: Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum (1995) 38(2):190-200.
7. Ferguson PJ, Martin EN, Greene KL, Kuhn S, Cafiso DS, Addona G, Taylor RP. Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys. J Immunol (1995) 155(1):339-347.
8. Pincus SE, Lukacher N, Mohamed N, Sesay M, Zabinski R, Ebelle R, Duncan L, Li J, Chen X, Peng W, Adaelu J et al: Evaluation of antigen-based heteropolymer for treatment of systemic lupus erythematosus in a nonhuman primate model. Clin Immunol (2002) 105 2):141-154.
9. Taylor RP, Sutherland WM, Reist CJ, Webb DJ, Wright EL, Labuguen RH. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment. Proc Natl Acad Sci USA (1991) 88 8):3305-3309.
10. Taylor RP, Sutherland WM, Martin EN, Ferguson PJ, Reinagel ML, Gilbert E, Lopez K, Incardona NL, Ochs HD: Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol (1997) 158(2):842-850.
11. Taylor RP, Martin EN, Reinagel ML, Nardin A, Craig M, Choice Q, Schlimgen R, Greenbaum S, Incardona NL, Ochs HD: Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol (1997) 159(8):4035-4044.
12. Hahn CS, French OG, Foley P, Martin EN, Taylor RP: Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia. J Immunol (2001) 166(2):1057-1065.
13. Lindorfer MA, Nardin A, Foley PL, Solga MD, Bankovich AJ, Martin EN, Henderson AL, Price CW, Gyimesi E, Wozencraft CP, Goldberg JB et al: Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol (2001) 167(4):2240-2249.
14. Reist CJ, Combs MJ, Croft BY, Taylor RP: Antigens pre-bound to the primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation. Eur J Immunol (1993) 23(11):3021-3027.
15. Reist CJ, Liang HY, Denny D, Martin EN, Scheld WM, Taylor RP: Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. Eur J Immunol (1994) 24(9):2018-2025.
16. Nelson RA Jr: The immune-adherence phenomenon; a hypothetical role of erythrocytes in defence against bacteria and viruses. Proc Natl Acad Sci USA (1956) 49(1):55-58.
17. Rothman IK, Gelfand JA, Fauci AS, Frank MM: The immune adherence receptor: Dissociation between the expression of erythrocyte and mononuclear cell C3b receptors. J Immunol (1975) 115 5):1312-1315.
18. Medof ME, Iida K, Mold C, Nussenzweig V: Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 156(6):1739-1754.
19. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 249(4965):146-151.
20. Paccaud JP, Carpentier JL, Schifferli JA: Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol (1988) 141(11):3889-3894.
21. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ: Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol (1985) 135 3):2005-2014.
22. Schifferli JA, Taylor RP: Physiological and pathological aspects of circulating immune complexes. Kidney Int (1989) 35 4):993-1003.
23. Ehlenberger AG, Nussenzweig V: The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 145(2):357-371.
24. Frank MM: The complement system in host defense and inflammation. Rev Infect Dis (1979) 1(3):483-501.
25. Cornacoff JB, Zager RA, Hebert LA: Mechanism of binding of immune complexes to human erythrocytes. Clin Res (1981) 29 Abs 364.
26. Reinagel ML, Gezen M, Ferguson PJ, Kuhn S, Martin EN, Taylor RP: The primate erythrocyte complement receptor (CR1) as a privileged site: Binding of immunoglobulin G to erythrocyte CR1 does not target erythrocyte for phagocytosis. Blood (1997) 89 3):1068-1077.
27. Taylor RP, Nardin A, Sutherland WM: Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor. Cancer Immunol Immunother (1997) 45(3-4):152-155.
28. Taylor RP, Ferguson PJ, Martin EN, Cooke J, Greene KL, Grinspun K, Guttman M, Kuhn S: Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clin Immunol Immunopathol (1997) 82 1):49-59.
29. Kimberly RP, Edberg JC, Merriam LT, Clarkson SB, Unkeless JC, Taylor RP: In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest (1989) 84(3):962-970.
30. Kuhn SE, Nardin A, Klebba PE, Taylor RP: Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. J Immunol (1998) 160(10):5088-5097.
31. Wright SD: CD14 and innate recognition of bacteria. J Immunol (1995) 155(1):6-8.
32. Arnaout MA, Melamed J, Tack BF, Colten HR: Characterization of the human complement (C3b) receptor with a fluid phase C3b dimer. J Immunol (1981) 127(4):1348-1354.
33. Ahearn JM, Fearon DT: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol (1989) 46:183-219.
34. Edberg JC, Tosic L, Wright EL, Sutherland WM, Taylor RP: Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. J Immunol (1988) 141(12):4258-4565.
35. Chevalier J, Kazatchkine MD: Distribution in clusters of complement receptor type one (CR1) on human erythrocytes. J Immunol (1989) 142(6):2031-2036.
36. Nardin A, Schlimgen R, Holers VM, Taylor RP: A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur J Immunol (1999) 29(5):1581-1586.
37. Cosio FG, Shen XP, Birmingham DJ, Van Aman M, Hebert LA: Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol (1990) 145(12):4198-4206.
38. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Walport MJ: A study of in vivo immune complex formation and clearance in man. J Immunol (1990) 144 12):4613-4620.
39. Craig ML, Bankovich AJ, Taylor RP: Visualization of the transfer reaction: Tracking immune complexes from erythrocyte complement receptor 1 to macrophages. Clin Immunol (2002) 105 1):36-47.
40. Henderson AL, Lindorfer MA, Kennedy AD, Foley PL, Taylor RP: Concerted clearance of immune complexes bound to the human erythrocyte complement receptor: Development of a heterologous mouse model. J Immunol Methods (2002) 270(2):183-197.
41. Powers JH, Buster BL, Reist CJ, Martin E, Bridges M, Sutherland WM, Taylor RP, Scheld WM: Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1. Infect Immun (1995) 63(4):1329-1335.
42. Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP: Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett (2004) 95 2):185-192.
43. Mohamed N, Li J, Ferreira C, Maassen C, Patterson J, Georgiou G, Iverson B, Casey L, Spitalny G: Heteropolymers as immunotherapy for anthrax toxemia. The 5th International Conference on Anthrax, Nice, France (2003): March 30-April 03.
44. Jones S, Li J, Ferreira C, Shah K, Lee S, Pincus S, Spitalny G, Casey L, Kreiswirth B, Mohamed N: Complete protection against Staphylococcus aureus bacteremia using a novel dual antibody therapeutic approach. ICAAC (2004) 44:Abs F-724.
45. Nardin A, Sutherland WM, Hevey M, Schmaljohn A, Taylor RP: Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes. J Immurnol Methods (1998) 211(1-2):21-31.
46. Repik A, Pincus SE, Ghiran I, Nicholson-Weller A, Asher DR, Cerny A, Casey LS, Jones SM, Jones SN, Mohamed N, Klickstein LB et al A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005): in press.
47. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM: Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun (2003) 71(12):6864-6870.
48. Fattom AI, Sarwar J, Ortiz A, Naso R: A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun (1996) 64(5):1659-1665.
49. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T: Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis (2001) 184(12):1572-1580.
50. Patti JM: Monoclonal antibodies as "First Line" therapy for severe S. aureus infection. ICAAC (2004) 44:Abs 1287.
51. Mond J: Phase I/II double bind, placebo controlled, dose escalation, safety and pharmacokinetics study in very low birth weight neonates of BSYX-A110, an anti-staphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infection. ICAAC (2004) 44:Abs; 1289.
52. Lowy FD: Staphylococcus aureus infections. N Engl J Med (1998) 339(8):520-532.
53. Greenberg DP, Bayer AS, Cheung AL, Ward JI: Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model. Infect Immun (1989) 97(4):1113-1118.
54. Mohamed N, Jones S, Li J, Ferreira C, Chen X, Kreiswirth B, Casey L, Spitalny G, Pincus S: Heteropolymers: A new class of therapeutics for treating bacterial and viral infections. Scientific Conference for Chemical and Biological Defense Research, Hunt Valley, MD, USA (2004): November 15-18.
55. Hecht B, Siegel N, Adler M, Kashgarian M, Hayslett JP: Prognostic indices in lupus nephritis. Medicine (1976) 55 2):163-181.
56. Bootsma H, Spronk PE, Ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, Kallenberg CG: The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis (1997) 56(11):661-666.
57. Wallace DJ: Management of lupus erythematosus: Recent insights. Curr Opin Rheumatol (2002) 14(3):212-219.
58. Taylor RP, Reist CJ, Sutherland WM, Otto A, Labuguen RH, Wright EL: In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor. J Immunol (1992) 148(8):2462-2468.
59. Iking-Konert C, Stocks S, Weinsberg F, Engelbrecht R, Bleck E, Pemiok A, Fischer-Betz R, Pincus S, Nardone L, Schneider M: First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: Safety and proof of principle of the antigen-heteropolymer ETI-104. Ann Rheum Dis (2004) 63(9):1104-1112.
60. Wold RT, Young FE, Tan EM, Farr RS: Deoxyribonucleic acid antibody: A method to detect its primary interaction with deoxyribonucleic acid. Science (1968) 161(843):806-807.